Patent intelligence · US
US 12226474
Methods and compositions for treating infections
Methods and compositions for treating infections
Patent details — US 12226474
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 18, 2025
- Expiration
- Feb 13, 2045
- Applicant
- Decoy Therapeutics Inc.
- Claims
- 7
- CPC classes
- A61K, A61K2039/6018, A61K2039/627, A61K39/215
Quick answer
US 12226474 (Methods and compositions for treating infections) is held by Decoy Therapeutics Inc.. Status: granted. Granted Feb 18, 2025. Expires Feb 13, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Decoy Therapeutics Inc.
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K2039/6018, A61K2039/627, A61K39/215
More from Decoy Therapeutics Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11147844
Methods of treatment of infections using bacteria
granted -
US 11045504
Compositions and methods for treatment of cancer using bacteria
granted -
US 10195259
Compositions and methods for treatment of cancer using bacteria
granted -
US 10052371
Compositions and methods for treatment of cancer using bacteria
granted -
US 9265804
Compositions and methods for treatment of cancer using bacteria
granted
Frequently asked questions
What is US patent 12226474?
US 12226474 (Methods and compositions for treating infections) is held by Decoy Therapeutics Inc.. Status: granted. Granted Feb 18, 2025. Expires Feb 13, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12226474?
Decoy Therapeutics Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 12226474 expire?
Our index shows an expiration date of Feb 13, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.